Chinese patent novel coronavirus vaccine, a recombinant human adenovirus with human replication deficiency, was applied for by the Military Medical Research Institute of the Chinese Academy of people’s Liberation Army and Conchino biological company in August 16th.
It is reported that the patent was applied for on March 18, 2020 and approved on August 11, 2020. The applicants are Chen Wei, Wu Shipo, Hou Lihua, Zhang Zhe and others. It can be seen that the vaccine is the adenovirus vector vaccine (Ad5 ncov vaccine) developed by academician Chen Wei’s team.
A novel coronavirus vaccine based on human 5 replication defective adenovirus is provided.
The vaccine takes replication deficient adenovirus type 5 with E1 and E3 joint deletion as the vector, and HEK293 cell line integrating adenovirus E1 gene as packaging cell line. The protective antigen gene carried by the vaccine is the optimized 2019 novel coronavirus coronavirus (sars-cov-2) s protein gene (Ad5 ncov).
After optimization, the expression level of S protein gene in transfected cells increased significantly. The vaccine has good immunogenicity in mice and guinea pigs, and can induce strong cellular and humoral immune responses in a short time.
The protective effect of novel coronavirus in hACE2 transgenic mice showed that the Ad5-nCoV14 load after single immunization could significantly reduce the viral load in the lung tissue, indicating that the vaccine had good immune protection effect against the 2019 new coronavirus. In addition, the preparation of the vaccine is rapid and simple, and can be used in large-scale production in a short period of time to deal with sudden outbreaks.
According to relevant reports, Chen Wei, academician of the Chinese Academy of engineering and researcher of the Academy of Military Sciences, won the national honorary title of “people’s hero” on August 11. She led the team to research and develop the recombinant new crown vaccine, and advanced into phase I and phase II clinical trials at home and abroad, respectively, to verify the safety and immunogenicity of the vaccine. At present, the phase III international clinical trial of the vaccine is progressing orderly.